​

Adaptimmune Therapeutics Ownership | Who Owns Adaptimmune Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Adaptimmune Therapeutics Ownership Summary

Adaptimmune Therapeutics is owned by 2.77% institutional investors, 0.30% insiders, and 96.93% retail investors. Bank of america corp /de/ is the largest institutional shareholder, holding 1.92% of ADAP shares. Edinburgh Worldwide Ord is the top mutual fund, with 2.00% of its assets in Adaptimmune Therapeutics shares.

ADAP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockAdaptimmune Therapeutics2.77%0.30%96.93%
SectorHealthcare Stocks 76.79%9.87%13.34%
IndustryBiotech Stocks 60.64%9.74%29.62%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bank of america corp /de/4.65M1.92%$4.53M
Ecor1 capital27.40M1.79%$14.76M
Long focus capital management20.49M1.34%$11.04M
Two seas capital lp20.53M1.33%$4.04M
Nea management company17.08M1.11%$3.36M
Mpm asset management5.56M0.36%$2.99M
Bioimpact capital4.89M0.32%$964.19K
Morgan stanley440.83K0.18%$429.77K
Renaissance2.53M0.16%$1.36M
Rock springs capital management lp2.48M0.16%$1.34M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mpm asset management5.56M2.41%$2.99M
Ecor1 capital27.40M0.56%$14.76M
Long focus capital management20.49M0.36%$11.04M
Nea management company17.08M0.26%$3.36M
Bioimpact capital4.89M0.17%$964.19K
Two seas capital lp20.53M0.13%$4.04M
Key client fiduciary advisors255.36K0.06%$137.56K
Rock springs capital management lp2.48M0.05%$1.34M
Columbia advisory partners16.42K0.01%$8.85K
Prosperity wealth management21.87K0.00%$11.78K

Top Buyers

HolderShares% AssetsChange
Long focus capital management20.49M0.36%7.19M
Two seas capital lp20.53M0.13%5.69M
Renaissance2.53M0.00%869.95K
Acadian asset management510.22K0.00%510.22K
Ubs group141.74K-139.93K

Top Sellers

HolderShares% AssetsChange
Matrix capital management company, lp---37.68M
Baillie gifford---11.82M
Pfm health sciences, lp---4.87M
Baker bros. advisors lp---2.34M
Tang capital management---1.74M

New Positions

HolderShares% AssetsChangeValue
Acadian asset management510.22K0.00%510.22K$269.00K
Raymond james financial31.08K-31.08K$16.74K
Clear harbor asset management18.52K0.00%18.52K$9.98K

Sold Out

HolderChange
National bank of canada /fi/-10.00
Northwestern mutual wealth management-69.00
Royal bank of canada-700.00
Ifp advisors-3.02K
Wetzel investment advisors-6.00K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20255-93.83%42,678,699-65.69%24.21%2-93.55%2-90.48%
Dec 31, 202479-2.47%124,313,247-18.02%88.30%30-18.92%2140.00%
Sep 30, 202479-1.25%151,643,820-1.46%591.46%3656.52%15-31.82%
Jun 30, 202480-3.61%153,896,694-5.05%631.25%23-32.35%22-
Mar 31, 2024839.21%162,089,97112.87%710.64%3421.43%22-12.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Edinburgh Worldwide Ord5.28M2.00%-
Baillie Gifford Global Discovery A Acc3.29M1.28%-20.71K
Baillie Gifford WW Discovery B USD Acc1.59M0.62%-6.22K
JPM Thematics Genetic Thrps C2 Acc USD913.17K0.36%-26.08K
JPM Thematics Genetic Thrps C2 dist USD881.69K0.34%-
Galileo - Biotech Innovation Fund S USD752.46K0.29%-
Mercer Global Small Cap Equity M-5£635.81K0.25%-
Mercer Global Small Cap Equity M-3£484.78K0.19%84.40K
SPDR® Portfolio Developed Wld ex-US ETF280.02K0.11%-
SEI International Equity F (SIT)246.74K0.09%-

Recent Insider Transactions

DateNameRoleActivityValue
Jan 17, 2025Norry Elliot Chief Medical OfficerSell$3.24K
Jan 17, 2025Lunger John Chief Patient Supply OfficerSell$3.24K
Jan 17, 2025Bertrand William C JR Chief Operating OfficerSell$3.24K
Jan 17, 2025Rawcliffe Adrian Chief Executive OfficerSell$17.77K
Jan 13, 2025Rawcliffe Adrian Chief Executive OfficerSell$7.37K

Insider Transactions Trends

DateBuySell
2025 Q1-17
2024 Q3--
2024 Q2-1
2024 Q1-19
2023 Q4--

ADAP Ownership FAQ

Who Owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics shareholders are primarily institutional investors at 2.77%, followed by 0.30% insiders and 96.93% retail investors. The average institutional ownership in Adaptimmune Therapeutics's industry, Biotech Stocks , is 60.64%, which Adaptimmune Therapeutics falls below.

Who owns the most shares of Adaptimmune Therapeutics?

Adaptimmune Therapeutics’s largest shareholders are Bank of america corp /de/ (4.65M shares, 1.92%), Ecor1 capital (27.4M shares, 1.79%), and Long focus capital management (20.49M shares, 1.34%). Together, they hold 5.05% of Adaptimmune Therapeutics’s total shares outstanding.

Does Blackrock own Adaptimmune Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Adaptimmune Therapeutics.

Who is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.41% of its assets in 5.56M Adaptimmune Therapeutics shares, valued at 2.99M$.

Who is the top mutual fund holder of Adaptimmune Therapeutics shares?

Edinburgh Worldwide Ord is the top mutual fund holder of Adaptimmune Therapeutics shares, with 2.00% of its total shares outstanding invested in 5.28M Adaptimmune Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools